Morning Brief — Friday, August 7, 2026

Market Overview

A strong batch of earnings reports from enterprise software names — Atlassian, Cloudflare, Twilio, and Doximity — is powering a risk-on tone in pre-market trading, with S&P futures up ~0.3%. A surprise July jobs report showing unexpected job losses is cooling rate-hike fears and giving the Fed room to pivot, acting as a secondary tailwind for growth stocks. The macro/micro combo is favorable today, though the Trade Desk’s implosion is a reminder that the market remains brutally selective — beat-and-raise or go home.

Claude’s Call

UP — The combination of a soft jobs print killing rate-hike bets and a genuine earnings-driven rally in enterprise software creates enough positive momentum to push the S&P 500 higher today; this isn’t a short-squeeze pop but a fundamental re-rating of AI-enabled software that has real staying power into the weekend.

Top Movers

DOCS (+79.82%) — $37.15 → $42.36 (+14.0% upside) Thesis: This is the real deal — Doximity dropped a revenue beat, raised full-year guidance, AND had the CEO flex on AI performance benchmarks (4.8% error rate vs. Anthropic’s 13.6%). That trifecta is why you get an 80% gap-up. The stock is printing at its 6-month and 20-day highs simultaneously, which is a clean breakout on massive volume (4.18x average). The AI credibility angle is particularly powerful — this isn’t vaporware, it’s a clinical AI outperforming frontier models in a defensible vertical. Levels: Exit at fib 1.272 extension $42.36 — that’s the next natural resistance. Support at fib 23.6% retracement $32.63; below that is $29.84 (38.2%). Do NOT chase above $42 without a pullback.

IOVA (+43.09%) — $6.21 → $7.54 (+21.4% upside) Thesis: Iovance delivered a 66% YoY revenue jump with record gross margins of 56% for its Amtagvi TIL therapy — this is a commercial-stage biotech inflecting, not a clinical-stage lottery ticket. Buyout buzz is circulating post-print, which adds a speculative premium that’s not entirely irrational given the asset quality. Stock hit a 52-week high and sits at the top of its 6-month range. Volume note: vol_vs_avg is unusually low (0.19) suggesting the institutional buying wave may not be exhausted. Levels: Exit at fib 1.272 extension $7.54. Support at fib 38.2% retracement $4.96 and SMA-50 at $4.41. Tight setup — the 23.6% fib at $5.53 is your first real test on any pullback.

TEAM (+36.21%) — $150.07 → $175.76 (+17.1% upside) Thesis: Atlassian’s print is being called a “game changer” for enterprise software — and it deserves that label. The read-through is sector-wide: AI is augmenting collaboration tools, not replacing them. TEAM is up 48.6% on the week and printing 6-month highs at $150.40, breaking out of a massive base from the $57 lows. At 32x forward earnings on 31.7% growth, the PEG of ~1.0 is actually reasonable — that’s fair value, not a bubble. Peers like Datadog and Snowflake should re-rate in sympathy. Levels: Exit at fib 1.272 extension $175.76. First support at fib 23.6% at $128.39, which also aligns with the prior breakout zone. SMA-50 at $93.73 is a distant floor. Chasing today is aggressive but the breakout is technically clean.

INSM (+33.86%) — $132.55 → $184.77 (+39.4% upside) Thesis: Brinsupri revenue of $309.2M in Q2 — up 49% sequentially — with full-year guidance raised to $1.25-$1.4B and peak sales estimates lifted to $7B+. Net loss shrank from $321M to $13M YoY — this company is approaching profitability faster than consensus expected. The 296% YoY revenue growth is extraordinary for a commercial-stage biopharma. The forward P/E of 592x looks absurd until you realize this is a standard pre-profit biopharma that’s almost profitable — the EV/Revenue framework matters more here. Levels: Exit at fib 1.272 extension $184.77. Current price is below the 6-month high of $164.91 — technically there’s a gap to fill back to $164 first, then the extension. SMA-50 at $105.30 is strong long-term support. Watch $147.67 (fib 23.6%) as near-term resistance turned support.

PAYC (+23.55%) — $215.97 → $246.95 (+14.3% upside) Thesis: Paycom’s Q2 beat was broad-based — recurring revenue growth, expanding margins, raised 2026 outlook, and FCF guidance above $650M. The automation angle (their AI-driven payroll automation is actually cutting clients’ manual work, creating stickiness) is structurally bullish. At a forward P/E of 15.8x on ~10% growth with a PEG of ~1.6x, it’s fairly valued — not cheap, but not stretched. The stock is at its 6-month high with SMA-50 at $144.73 far below. Levels: Exit at fib 1.272 extension $246.95. Support at fib 23.6% retracement $193.57 — that’s your stop zone. The move is legitimate but the stock has nearly doubled from the 6-month low; take partials into $247.

TWLO (+21.12%) — $233.99 → $274.82 (+17.4% upside) Thesis: Twilio beat on Q2 and raised full-year guidance as voice-based AI tools are gaining traction — this is a real fundamental re-rating, not sympathy. Critically, TWLO’s RSI of 19.3 is deeply oversold on a relative basis despite today’s 21% move, suggesting the stock was badly beaten down before this print. This is a genuine buy-the-dip-off-an-earnings-beat setup. The 6-month base from $108 to today’s $239 is a massive recovery. Levels: Exit at fib 1.272 extension $274.82. Support at fib 23.6% retracement $208.39 (also near SMA-50 at $203.24). The RSI being this low despite the pop means the stock has room to normalize higher.

SITM (+26.58%) — $687.50 → $1,062.03 (+54.5% upside) Thesis: SiTime absolutely destroyed Q2 estimates — revenues up 127% YoY, driven by CED (Communications, Enterprise, and Data Center) growth, with expanding margins and a Renesas deal strengthening Q3 visibility. The problem: at 49x forward earnings and EV/EBITDA of 388x vs. a peer median of 32x, SITM is EXPENSIVE. The stock is also well below its 6-month high of $901, meaning it’s actually recovering from a deep hole. The 127% revenue growth makes the valuation less insane — PEG is roughly 0.4x on that growth rate. Levels: Exit at fib 1.272 extension $1,062 (ambitious). More realistic near-term target: prior resistance near $762 (fib 23.6%). Support at fib 38.2% at $676 and SMA-50 at $639. This is volatile — size accordingly.

MGNI (+17.66%) — $24.32 → $29.08 (+19.6% upside) Thesis: Magnite is the direct beneficiary of the Trade Desk’s disaster — as TTD implodes on a weak Q2 and guidance cut, programmatic ad spend is being reallocated and Magnite is picking up the narrative. MGNI’s own Q2 showed a dramatic profitability surge (H1 net income up from $1.5M to $23.8M) — this is a real fundamental story, not just sympathy. RSI at 32 is technically oversold, suggesting the recent base-building was overdone and today’s move is a mean reversion. Levels: Exit at fib 1.272 extension $29.08. Support at fib 23.6% at $21.94 and SMA-50 at $18.51. Solid risk/reward with a clear catalyst.

CACI (+21.38%) — $628.79 → $690.72 (+9.8% upside) Thesis: CACI delivered 17.6% revenue growth in Q4 with strong contract awards and double-digit growth guidance for FY27 — defense IT is on fire as government AI spending ramps. The stock is near its 6-month high of $637 and the fib 1.272 extension at $690 is the next logical target. This is a steady compounder with a genuine secular tailwind, not a momentum gamble. Levels: Exit at fib 1.272 extension $690.72. Support at fib 23.6% at $590.89 and SMA-50 at $496.88. Conservative but clean.

WPP (+25.91%) — $25.95 → $29.72 (+14.5% upside) Thesis: WPP’s restructuring is gaining visible traction — revenue declines are slowing materially in Q2, suggesting the worst is behind the ad holding company. At 6-month highs with SMA-50 at $18.67 far below, this is a clean breakout. The broader ad-tech context is mixed (Trade Desk disaster vs. Magnite strength), but WPP is playing in traditional/digital agency, not pure-play programmatic. The move may be overdone short-term but the turnaround narrative has legs. Levels: Exit at fib 1.272 extension $29.72. Support at fib 23.6% retracement $23.72. Don’t chase above $27 without a pullback to $23-24 first.

Headlines to Watch

“Atlassian results seen as ‘game changer’ for AI kills software worries” — This is the most important read-through headline today; if TEAM’s print signals AI augments SaaS rather than destroys it, the entire software sector deserves a multiple re-rating — watch DDOG, SNOW, and CRM for sympathy moves.
“TTD Stock Plunges Nearly 30% Premarket As ‘Awful’ Q2 Sparks Wave Of Wall Street Downgrades” — Trade Desk’s collapse is a brutal reminder that ad-tech is bifurcating: connected TV / CTV winners (Magnite) vs. DSP losers; this also removes a key benchmark stock from the space, potentially redirecting institutional capital.
“US stocks set for higher open as surprise payrolls fall cools rate-hike bets” — A negative July jobs print is the macro gift growth bulls needed; lower-for-longer rates are the single biggest valuation driver for high-multiple tech names on today’s mover list.
“DOCS Stock Soars After CEO Says Clinical AI Outperformed Anthropic” — CEO benchmarking against Anthropic directly is a bold but specific claim that could attract both institutional AI-thematic buyers and skeptical shorts — the debate around this data point will drive DOCS volatility all day.
“Insmed (INSM) Soars 33.86% as Brinsupri Drives Fourfold Growth” — With peak sales estimates now above $7B, Insmed is moving from speculative biopharma to potential large-cap pharma — expect M&A speculation to build, which could create a sustained bid.
“SNDK, WDC Rout Tests Chip Rally — ‘Beat And Raise Is Not Enough’“ — The memory chip sector is suffering a “beat and raise isn’t enough” hangover; this is a serious warning for other semis trading at elevated multiples — watch NVDA’s reaction as a sector barometer.
“Trump Calls AI ‘Bigger Than Oil’ In the Race Against China For Tech, Crypto Dominance” — Political tailwind for AI infrastructure spending; this type of executive-level commentary tends to accelerate federal procurement cycles and benefits defense IT names like CACI and Booz Allen.

Claude’s Top Picks

TWLO (+21.12% today, +18.57% week) — $233.99 → $274.82 (+17.4% upside) Valuation: No direct comp provided, but Twilio’s enterprise communications platform trades at a discount to pure-play SaaS peers given its history of margin compression — the AI-driven revenue acceleration changes that narrative. Upside: RSI of 19.3 before today’s move signals the stock was genuinely oversold; raised guidance plus voice AI traction gives this a multi-quarter re-rating story, not just a one-day bounce. Risk: If voice AI adoption stalls or the guidance raise proves conservative in Q3, the stock could revisit the $183-208 support zone quickly.

INSM (+33.86% today, +30.60% week) — $132.55 → $184.77 (+39.4% upside) Valuation: Technically EXPENSIVE on forward P/E at 592x vs. peer median 14x, but this metric is irrelevant for a company transitioning from a $321M loss to near-breakeven in 12 months — EV/Revenue and pipeline value are the right frameworks, and $14B combined peak sales estimates justify a much larger market cap. Upside: Brinsupri’s 49% sequential growth trajectory and a raised full-year guide to $1.25-$1.4B suggest this is still early in the commercial ramp, with lung disease indications providing a massive TAM. Risk: Biotech giveback risk is real — if the market rotates out of risk or Q3 NCFB scripts disappoint, this could retrace to the $105 SMA-50 area quickly given its volatility history.

MGNI (+17.66% today, +25.43% week) — $24.32 → $29.08 (+19.6% upside) Valuation: No forward P/E comp provided, but with H1 net income surging from $1.5M to $23.8M, Magnite is rapidly becoming a profitable ad-tech name trading at a fraction of peak multiples — materially undervalued relative to its profitability inflection. Upside: TTD’s collapse is structural market share donor to Magnite in the CTV/programmatic space; RSI at 32 means the stock is technically recovering from oversold conditions, and the combination of real earnings + competitor implosion is a rare double catalyst. Risk: If the ad market broadly weakens (as TTD’s guidance implies), even Magnite can’t fully escape macro headwinds, and the stock could pull back to SMA-50 at $18.51 on a risk-off day.

CACI (+21.38% today, +31.73% week) — $628.79 → $690.72 (+9.8% upside) Valuation: No comp data provided, but government IT services historically trade at 15-20x earnings and CACI’s double-digit growth warrants a premium — the AI-enabled defense contract cycle is a durable tailwind that peers like Leidos and Booz Allen validate. Upside: Record contract awards, 17.6% Q4 revenue growth, and a FY27 double-digit growth outlook in a sector with high government spending visibility makes this one of the more predictable compounders on the list. Risk: Any federal budget continuing resolution or DOGE-related defense IT spending cuts could compress forward estimates — the stock is near its 6-month high and pricing in a lot of good news at $637.

FIGS (+35.59% today, +42.43% week) — $15.24 → $19.26 (+26.4% upside) Valuation: No comp provided, but FIGS’ 28.8% revenue growth with a 57% EPS beat above estimates suggests the market badly underestimated demand recovery for healthcare apparel — the stock is still 11% below its 6-month high of $17.12, leaving room to reclaim prior peaks. Upside: The RSI at 36 (technically still oversold territory) combined with a massive EPS beat and raised guidance suggests institutional investors are still rebuilding positions — this isn’t a crowded trade yet. Risk: FIGS is a consumer discretionary-adjacent name (healthcare workers buying premium scrubs); any macro slowdown narrative or promotional pricing pressure could compress margins and reverse the guidance raise.

Avoid

DOCS — Already up 80% in a single session to its 6-month high with fib 1.272 extension the only upside target at $42.36; chasing here on day one risks a violent fade as early holders take profits, and the RSI at 50 (neutral, not oversold) offers no technical edge for new entries.

AEVA — Despite a “transformational hyperscaler deal” headline, AEVA is a pre-profit lidar company with only 11.3% revenue growth, a negative forward P/E, and vol_vs_avg of just 0.08 — the 28.8% move on thin volume and speculative deal news is a classic “buy the rumor” trap with no concrete revenue contribution timeline disclosed.

SITM — The 127% revenue growth story is legitimate, but at EV/EBITDA of 388x versus a peer median of 32x, this is more than 10x expensive relative to semis peers; the stock is also recovering from a 46% decline from its 6-month high of $901, meaning the prior institutional base bought in the $700-$900 range has months of overhead supply to work through.

WSB Sentiment Check

HTZ — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — Hertz is a zombie-debt story with the stock at $2.32, down from a $7.81 6-month high, sitting 63% below even its near-term SMA-50 of $3.12; with 2,260 mentions and 11,615 upvotes, this has the fingerprints of a retail short-squeeze attempt on a fundamentally impaired car rental company — the fib support levels are all far above current price, meaning the chart is in free-fall, not a base, and the 2021 meme playbook doesn’t apply here.

SPCX — WSB says: MIXED (55% bullish) Claude says: PARTIALLY — SPCX is a space sector ETF/stock down to $118.87 from a $211.39 6-month high, sitting below all major fib supports (lowest is $147.66 fib 61.8%) — technically it’s in a downtrend and the mixed WSB sentiment correctly reflects the lack of conviction; the space sector has structural tailwinds but this vehicle has been a value destroyer recently.

MU — WSB says: BEARISH (30% bullish) Claude says: AGREE — Micron at $884.75 is below its 50-day SMA of $971 and the fib 38.2% support at $872.77 is being tested; the SNDK/WDC “beat and raise isn’t enough” narrative is spilling over to MU, and WSB’s 70% bearish read is technically supported — the semiconductor memory cycle peak-fear is real and MU faces meaningful downside to the $767 fib 50% level.

SNDK — WSB says: BEARISH (30% bullish) Claude says: AGREE — SanDisk at $1,272 is sitting 45% below its 6-month high of $2,335 and below every major fib support level down to $1,217 (fib 61.8%), with SMA-50 at $1,689 acting as overhead resistance; despite beating earnings, the “beat and raise isn’t enough” reaction validates WSB’s bear case — this is a falling knife in a deteriorating memory market narrative.

NVDA — WSB says: BEARISH (30% bullish) Claude says: PARTIALLY — NVDA at $222.04 is actually holding above its fib 23.6% support at $218.83 and above SMA-50 at $206.01, so the technical picture is more neutral than WSB’s bearish 70% implies; yes, the stock is below its $235.47 6-month high but the AI infrastructure spending narrative (reinforced by Trump’s comments today) provides a real floor — I’d call this consolidation, not breakdown.

Earnings Scorecard

NET (Cloudflare) — REPORTED | Stock: +12.43% Reaction justified and arguably insufficient — Cloudflare beat on Q2 and raised full-year guidance on strong AI demand; a 12% reaction to a legitimate beat-and-raise from an AI-infrastructure critical name is actually measured, and the stock likely has further to run toward the analyst target of $272; buy the strength on any intraday pullback.

NVO (Novo Nordisk) — REPORTED | Stock: +2.90% Reaction appropriate but muted — the Wegovy pill pipeline update and raised outlook are incrementally positive, but NVO has been a Wall Street consensus long for years and the 2.9% reaction suggests the market expected more; analyst target of $47.35 suggests modest upside from here; hold but don’t add aggressively.

ANET (Arista Networks) — REPORTED | Stock: +1.52% Reaction underdone — Arista’s first-ever $3B revenue quarter is a genuine milestone and a 1.52% reaction is suspiciously small for that print; the muted reaction likely reflects positioning into the print rather than fundamental disappointment; analyst target of $238.63 near current price; hold and watch for a delayed re-rating.

WDC (Western Digital) — REPORTED | Stock: -1.25% Reaction justified and could get worse — the “beat and raise isn’t enough” narrative is explicitly calling out WDC/SNDK, and a -1.25% reaction on an earnings beat signals the market is discounting forward estimates; with SNDK already in freefall, Western Digital faces continued multiple compression; sell the rip on any bounce.

SPOT (Spotify) — REPORTED | Stock: +1.11% Reaction insufficient to the downside — Spotify missed on AI and marketing cost inflation, and a flat/+1.11% reaction suggests the market isn’t pricing in the margin compression story fully; at an analyst target of $607.75, there’s upside but cost discipline needs to improve; hold with caution, don’t add here.

AMD — REPORTED | Stock: +0.85% Reaction underdone — AMD posted $3.96 EPS and the 0.85% reaction feels like digestion after a big pre-earnings run; the AI GPU narrative remains intact and the analyst target of $608 implies meaningful upside; hold and buy the next pullback toward the 50-day SMA.

AMGN (Amgen) — REPORTED | Stock: -0.70% Reaction overdone to the downside — Amgen hiked sales outlook by $1 billion and the stock fell 0.7%; that’s a classic “sell the news” on a consensus-long name; at an analyst target of $374.69, the stock is likely near fair value and the negative reaction is a positioning flush; buy the dip for a mean-reversion trade.

SNDK (SanDisk) — REPORTED | Stock: +0.76% Reaction completely divorced from the chart — SNDK reported $73.75 EPS and is somehow only up 0.76% while the 6-month chart shows a 45% decline from the $2,335 high; the analyst target of $2,116 implies a massive theoretical recovery but the “beat isn’t enough” sentiment is overpowering fundamentals; avoid — this is a falling knife until the memory cycle narrative shifts.

CEG (Constellation Energy) — REPORTED | Stock: +0.59% Reaction underdone — CEG beat earnings, raised guidance to a $12.50 EPS outlook, and is potentially 26% undervalued per DCF models, yet the +0.59% reaction suggests nuclear/AI data center power is already priced in for many holders; analyst target of $351 implies real upside; buy the dip — this is a structural AI infrastructure play that the market is underweighting.

This brief is for informational purposes only and does not constitute investment advice. All targets and levels are for discussion purposes. Past performance does not guarantee future results.